Summit Therapeutics PLC (SMMT) — Capital Reinvestment Ratio
Summit Therapeutics PLC (SMMT) has a Capital Reinvestment Ratio of 0.23x as of December 2022, meaning it reinvests 0% of its operating cash flow ($4.23 Million) in capital expenditures ($994.38K). Check Summit Therapeutics PLC tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Summit Therapeutics PLC Capital Reinvestment Ratio (2004–2016)
This chart tracks Summit Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see SMMT cash generation efficiency.
Annual Capital Reinvestment Ratio for Summit Therapeutics PLC (2004–2016)
Year-by-year Capital Reinvestment Ratio for Summit Therapeutics PLC from 2004 to 2016. See SMMT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2016 | 0.01x | $15.18 Million | $110.00K | ▼ -98.4% |
| 2004 | 0.44x | $29.74K | $13.18K | — |